AstraZeneca Plc Reports Positive Results Of Phase III THEMIS Trial For Brilinta     

AstraZeneca plc (LSE: AZN), has reported positive result of the Phase III THEMIS trial, where its medicine Brilinta (ticagrelor) indicted along with aspirin reduced the comparative risk for the composite of cardiovascular death, stroke or even heart attack by ten per cent compared with aspirin taken alone. Brilinta, the oral, reversible, direct-acting P2Y12 receptor antagonist, along with aspirin, is recommended for stopping atherothrombotic events in adult patients with the acute coronary syndrome.

On 2nd September 2019, at the time of writing, GMT 08:03 AM, AZN shares were trading at GBX 7,391.00, up by 73.00 points or 1.00% against the previous day closing price.